)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CRISPR Therapeutics
CRISPR Therapeutics (CRSP) investor relations material
CRISPR Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary2 Nov, 2026
Executive summary
Q3 2026 revenue was $12.7m and net loss was $111.4m; cash, cash equivalents and marketable securities totaled $2,276.6m at September 30.
CASGEVY generated $99m in Q3 revenue, up 30% quarter over quarter; more than 750 patients have initiated treatment worldwide.
Liquidity is expected to fund operating expenses and capital expenditures for at least 24 months, excluding potential collaboration receipts and future financing.
Pipeline progress included CTX310 RMAT designations, completed CTX611 Phase 2 enrollment and ongoing zugo-cel trials across autoimmune and cancer indications.
Financial highlights
Q3 consolidated revenue was $12.7m vs. $0.9m a year earlier; $12.3m reflected deferred collaboration revenue recognized after Vertex declined an option.
Q3 operating loss was $130.0m vs. $132.1m; net loss was $111.4m vs. $106.4m, including $11.7m of acquired in-process R&D expense for a Sirius milestone.
Q3 R&D expense was $71.9m vs. $58.9m, G&A was $17.9m vs. $16.9m, and collaboration expense, net, was $41.3m vs. $57.1m.
9M revenue was $24.3m vs. $2.6m; operating loss was $377.6m vs. $509.8m and net loss was $325.5m vs. $451.0m.
9M R&D expense rose to $207.6m from $201.3m, while collaboration expense fell to $127.5m from $159.8m, primarily as the share of CASGEVY revenue increased.
Outlook and guidance
Existing cash, cash equivalents and marketable securities are expected to fund operating expenses and capital expenditures for at least 24 months; estimate excludes additional financing and collaboration proceeds.
R&D and G&A costs may increase as programs advance, trials expand, candidates are added and commercialization preparations proceed.
CTX310 Phase 1b data and zugo-cel systemic sclerosis Phase 1 data were scheduled for November 2026 conferences; CTX611 and zugo-cel B-cell malignancy updates were anticipated in H2 2026.
An update on options to nominate up to two additional siRNA targets was expected in 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CRISPR Therapeutics
- CASGEVY and three late-stage assets drive growth, with pivotal data and global expansion ahead.CRSP
Morgan Stanley 24th Annual Global Healthcare Conference - CRISPR-Cas9 editing of ANGPTL3 achieved sustained lipid reductions with favorable safety at 1 year.CRSPCorporate presentation
- Revenue and liquidity surged in Q2 2026, with major clinical and regulatory milestones achieved.CRSPQ2 2026
- Broad CRISPR pipeline advances with commercial traction and key data readouts expected within a year.CRSPGuggenheim Securities Inaugural Healthcare Innovation Conference
- Strategic partnerships and advancing pipeline set up multiple near-term value catalysts.CRSPH.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
- Pipeline advances and financial strength drive growth, with profitability targeted by 2028.CRSPGuggenheim Securities 2nd Annual Healthcare Innovation Conference
- Five major clinical updates in cardiovascular and autoimmune set the stage for pivotal trials in 2027.CRSPGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Gene editing and CAR-T breakthroughs drive clinical and commercial momentum into 2026.CRSP44th Annual J.P. Morgan Healthcare Conference
- 2025 poised for major value creation with global launches, pivotal data, and pipeline expansion.CRSP43rd Annual J.P. Morgan Healthcare Conference 2025
Next CRISPR Therapeutics earnings date
Q4 202611 Feb, 2027
CRISPR Therapeutics
Next CRISPR Therapeutics earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Transforming medicine
CRISPR-Cas9 had its initial description ten years ago when a study revealed the potential of exploiting the system for RNA-programmable gene editing. It allows scientists to change the molecules that carry the instructions to produce proteins without changing the original DNA code.
The technology has its foundation in the natural defense mechanism of bacteria and single-celled microorganisms. When mentioned, CRISPR often links to Cas9, the protein that helps target and cut the genetic code to be edited. You can therefore see Cas9 as the genetic scissors cutting the DNA at a specific point, and once the gene is cut, there are two possible outcomes:
The cell repairs itself.
The researchers insert a new DNA template for the repair.
A true gene editing enabler?
CRISPR technology is transforming medicine, enabling us to treat and prevent many diseases. It also has the potential to be used to make precise changes, such as replacing faulty genes – true gene editing.
We have seen remarkable progress within this technology in the first ten years. As new editing technologies develop, we can insert larger DNA fragments more precisely, enabling us to tackle more of the 75,000 genetic variants associated with human disease. Some of CRISPR’s main competitors include Intellia Therapeutics, Denali Therapeutics, Vaxcyte, and Ginkgo Bioworks.